These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 18624046)

  • 21. Plasma fibroblast growth factor 23 and osteocalcin serum levels are associated with cardiovascular risk in HIV-1-infected patients receiving antiretroviral treatment.
    Spagnuolo V; Cocorullo D; Galli L; Bigoloni A; Galli A; Rubinacci A; Mignogna G; Carbone A; Lazzarin A; Castagna A
    J Antimicrob Chemother; 2013 Dec; 68(12):2960-3. PubMed ID: 23812682
    [No Abstract]   [Full Text] [Related]  

  • 22. HIV, highly active antiretroviral therapy and the heart: a cellular to epidemiological review.
    Lambert CT; Sandesara PB; Hirsh B; Shaw LJ; Lewis W; Quyyumi AA; Schinazi RF; Post WS; Sperling L
    HIV Med; 2016 Jun; 17(6):411-24. PubMed ID: 26611380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resistance to HIV drugs in UK may be lower in some areas.
    Fox JM; Fidler S; Weber J
    BMJ; 2006 Jan; 332(7534):179-80. PubMed ID: 16424507
    [No Abstract]   [Full Text] [Related]  

  • 24. Patterns of Immune Activation in HIV and Non HIV Subjects and Its Relation to Cardiovascular Disease Risk.
    Vos AG; Dodd CN; Delemarre EM; Nierkens S; Serenata C; Grobbee DE; Klipstein-Grobusch K; Venter WDF
    Front Immunol; 2021; 12():647805. PubMed ID: 34290695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of pharmaceutical care on cardiovascular risk among older HIV patients on antiretroviral therapy.
    Domingues EA; Ferrit-Martín M; Calleja-Hernández MÁ
    Int J Clin Pharm; 2017 Feb; 39(1):52-60. PubMed ID: 27864732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular risk factors and lifetime risk estimation in HIV-infected patients under antiretroviral treatment in Spain.
    Estrada V; Bernardino JI; Masiá M; Iribarren JA; Ortega A; Lozano F; Miralles C; Olalla J; Santos J; Elías MJ; Domingo P; Cruz AF
    HIV Clin Trials; 2015; 16(2):57-65. PubMed ID: 25874992
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV and noncommunicable cardiovascular and pulmonary diseases in low- and middle-income countries in the ART era: what we know and best directions for future research.
    Bloomfield GS; Khazanie P; Morris A; Rabadán-Diehl C; Benjamin LA; Murdoch D; Radcliff VS; Velazquez EJ; Hicks C
    J Acquir Immune Defic Syndr; 2014 Sep; 67 Suppl 1(0 1):S40-53. PubMed ID: 25117960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Evaluation of cardiovascular risk in HIV positive patients in a specialized center at Santiago, Chile].
    Lazcano C; Millacura JC; Saavedra F; Cortés CP
    Rev Chilena Infectol; 2016 Jun; 33(3):352-4. PubMed ID: 27598289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pulmonary disease in HIV-infected adults in the era of antiretroviral therapy.
    Fitzpatrick ME; Kunisaki KM; Morris A
    AIDS; 2018 Jan; 32(3):277-292. PubMed ID: 29194119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patterns of cardiovascular risk and disease in HIV-positive adults on anti-retroviral therapy in Mozambique.
    Dobe I; Manafe N; Majid N; Zimba I; Manuel B; Mocumbi A
    Cardiovasc J Afr; 2020; 31(4):190-195. PubMed ID: 32634198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular disease risk in an urban African population: a cross-sectional analysis on the role of HIV and antiretroviral treatment.
    Vos AG; Hoeve K; Barth RE; Peper J; Moorhouse M; Crowther NJ; Venter WDF; Grobbee DE; Bots ML; Klipstein-Grobusch K
    Retrovirology; 2019 Dec; 16(1):37. PubMed ID: 31796103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complications of HIV disease and antiretroviral treatment.
    Luetkemeyer AF; Havlir DV; Currier JS
    Top HIV Med; 2010; 18(2):57-65. PubMed ID: 20516525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluating and managing cardiovascular disease risk factors in HIV-infected patients.
    Top HIV Med; 2010 Dec; 18(5):164-8. PubMed ID: 21245517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular disease and toxicities related to HIV infection and its therapies.
    Zareba KM; Miller TL; Lipshultz SE
    Expert Opin Drug Saf; 2005 Nov; 4(6):1017-25. PubMed ID: 16255661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV infection and cardiovascular disease--is there really a link?
    Sklar P; Masur H
    N Engl J Med; 2003 Nov; 349(21):2065-7. PubMed ID: 14627792
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of a Structured Pharmaceutical Care Intervention Versus Usual Care on Cardiovascular Risk in HIV Patients on Antiretroviral Therapy: INFAMERICA Study.
    Morillo-Verdugo R; Robustillo-Cortés MLA; Martín-Conde MT; Callejón-Callejón G; Cid-Silva P; Moriel-Sánchez C; Tortajada-Goitia B; Almeida-González CV
    Ann Pharmacother; 2018 Nov; 52(11):1098-1108. PubMed ID: 29808711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of obesity and cardiovascular risk in patients with HIV/AIDS in Porto Alegre, Brazil.
    Kroll AF; Sprinz E; Leal SC; Labrêa Mda G; Setúbal S
    Arq Bras Endocrinol Metabol; 2012 Mar; 56(2):137-41. PubMed ID: 22584567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular Disease, Statins, and HIV.
    Eckard AR; Meissner EG; Singh I; McComsey GA
    J Infect Dis; 2016 Oct; 214 Suppl 2(Suppl 2):S83-92. PubMed ID: 27625435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heterosexual transmission of HIV-1 infection in UK.
    Barbaro G
    Lancet; 2001 Oct; 358(9291):1458. PubMed ID: 11705525
    [No Abstract]   [Full Text] [Related]  

  • 40. [Lipid alterations and cardiovascular risk associated with antiretroviral therapy].
    Masiá-Canuto M; Bernal-Morell E; Gutiérrez-Rodero F
    Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):637-48. PubMed ID: 17194390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.